- Home
- OGEN vs POAI Comparison
OGEN vs POAI Comparison
Compare OGEN & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- POAI
- Stock Information
- Founded
- OGEN 1996
- POAI 2002
- Country
- OGEN United States
- POAI United States
- Employees
- OGEN N/A
- POAI N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- OGEN Health Care
- POAI Health Care
- Exchange
- OGEN Nasdaq
- POAI Nasdaq
- Market Cap
- OGEN 4.5M
- POAI 4.9M
- IPO Year
- OGEN N/A
- POAI N/A
- Fundamental
- Price
- OGEN $0.32
- POAI $0.69
- Analyst Decision
- OGEN
- POAI Hold
- Analyst Count
- OGEN 0
- POAI 1
- Target Price
- OGEN N/A
- POAI N/A
- AVG Volume (30 Days)
- OGEN 738.8K
- POAI 119.5K
- Earning Date
- OGEN 11-13-2024
- POAI 11-12-2024
- Dividend Yield
- OGEN N/A
- POAI N/A
- EPS Growth
- OGEN N/A
- POAI N/A
- EPS
- OGEN N/A
- POAI N/A
- Revenue
- OGEN N/A
- POAI $1,484,223.00
- Revenue This Year
- OGEN N/A
- POAI N/A
- Revenue Next Year
- OGEN N/A
- POAI $502.91
- P/E Ratio
- OGEN N/A
- POAI N/A
- Revenue Growth
- OGEN N/A
- POAI N/A
- 52 Week Low
- OGEN $0.28
- POAI $0.55
- 52 Week High
- OGEN $7.74
- POAI $3.76
- Technical
- Relative Strength Index (RSI)
- OGEN 41.16
- POAI 44.88
- Support Level
- OGEN $0.30
- POAI $0.70
- Resistance Level
- OGEN $0.43
- POAI $0.89
- Average True Range (ATR)
- OGEN 0.03
- POAI 0.11
- MACD
- OGEN 0.01
- POAI 0.00
- Stochastic Oscillator
- OGEN 23.47
- POAI 14.64
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.